Movement Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

Data from the Michael J. Fox Foundation’s Fox Insight study reveal a number of consequences as a result of the virus for those with chronic neurologic diseases.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Claassen, MD, MS.

The 18F-PI-2620 radiotracer’s positive effect on diagnosing and differentiating patients with suspected progressive supranuclear palsy leaves questions about its potential as a PSP progression biomarker.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on the feasibility of genotyping, phasing, and targeting of SNPs in Huntington disease.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

Reduced amplitude and/or robustness of the rhythms, rather than disrupted timing, are the most indicative of a subsequent risk of PD, independent of nighttime sleep disturbances.

The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

During DBS stimulation “on” periods, all patients experienced varying degrees of dysphagia, with significant improvements when stimulation was “off.”

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

The Medtronic device is the only DBS system that is eligible to be used for both 3T and 1.5T full-body MRI scans, with the first implant procedure scheduled at Mayo Clinic.

New drug classes and formulations may help hold off breakthrough activity as the research community works to optimize levodopa delivery and absorption.

Neurology News Network for the week ending June 20, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

The newly developed MRI techniques aimed at treating those with Parkinson disease could lead to better outcomes and fewer side effects.

Neurology News Network for the week ending June 13, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The Adamas Pharmaceuticals agent has a PDUFA action date of February 1, 2021, as a treatment for off episodes in patients with Parkinson disease who are receiving levodopa-based therapy.

Post-hoc data presented at the EAN Congress suggest patients with dyskinesia prior to starting treatment on the Kyowa Kirin agent were more likely to experience dyskinesia as an adverse event during treatment.

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.